EFC16045 – A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with nonrelapsing secondary progressive multiple sclerosis (HERCULES)
This is approximately a 4-year study to compare the effectiveness of the study drug against a placebo. You will have a 66% chance that you get the study drug, and a 33% percent chance of getting a placebo, which is a pill that looks like the study drug but has no active ingredient. If it is confirmed during the study that your disease has progressed, you will be offered the study drug in an open-label fashion, which means you will know what you are taking. You may also choose, instead, to take another approved treatment for secondary progressive MS.
This trial is accepting new patients.
Basic Enrollment Criteria:
- 18 to 60 years of age
- Diagnosis of Non-relapsing Secondary Progressive MS
- Willing to comply with study visits and requirements